Spyre Therapeutics

SYREPhase 2

Spyre Therapeutics is pioneering a novel approach to treating IBD and rheumatological diseases by developing engineered antibodies designed for prolonged activity and convenient, infrequent dosing. Its core strategy involves targeting well-validated pathways—α4β7, TL1A, and IL-23—both as monotherapies and in innovative combinations, with the goal of achieving deeper remission for patients. The company is advancing a robust pipeline through its Phase 2 SKYLINE-UC trial and has built a leadership team with extensive experience in drug development and commercialization. Spyre's vision is to overcome the limitations of current therapies, such as low remission rates and frequent injections, by delivering superior efficacy and improved patient compliance.

Market Cap

$3.2B

Focus

AntibodiesBiologics

SYRE · Stock Price

USD 41.2517.25 (-29.49%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for engineering half-life extended monoclonal antibodies, enabling high-concentration formulations and co-formulated combinations for subcutaneous injection with potential quarterly or twice-annual dosing.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
SPY002-072 + Placebo	Rheumatoid Arthritis	Phase 2
SPY001 + SPY002 + SPY003	Ulcerative Colitis	Phase 2
SPY002-072	Healthy	Phase 1
SPY003-207	Healthy	Phase 1
SPY002-091	Healthy	Phase 1

Funding History

Total raised: $211M

IPO$86MUndisclosedJul 16, 2020

Series B$75MF-Prime CapitalJun 15, 2019

Series A$50MAtlas VentureJan 15, 2018

Opportunities

Spyre's primary growth opportunity lies in successfully demonstrating that its extended-dosing antibody platform can deliver superior efficacy and convenience in large, underserved markets like ulcerative colitis and rheumatoid arthritis.

Success could lead to significant market share capture, lucrative partnership deals for ex-U.S.

rights or specific indications, and expansion into adjacent immune-mediated diseases.

The combination therapy approach also offers a potential best-in-class product profile.

Risk Factors

Key risks include clinical failure of lead assets, inability to demonstrate a meaningful dosing advantage over competitors, intense competition from established therapies with strong physician loyalty, and the need for substantial additional capital to fund development.

The complexity of developing and commercializing combination products also presents regulatory and manufacturing challenges.

Competitive Landscape

Spyre faces intense competition from major pharmaceutical companies with entrenched products in IBD (e.g., Takeda's Entyvio, AbbVie's Skyrizi, J&J's Tremfya) and rheumatology. Its differentiation strategy is not based on novel targets but on creating a superior product profile through half-life extension, aiming for quarterly or twice-annual dosing versus the current standard of monthly or every-other-month injections. It must prove this profile delivers clinical benefits.